Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
21:18
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

13th International Conference on Malignant Lymphoma

 

17-20 June 2015 Lugano
FAQs
   
Discussion forum - 13th International Conference on Malignant Lymphoma
    Topic - Pre-clinical studies

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER.
 

Poster: 275
Visits: 59
Title: A variant of obinutuzumab with abolished ADCC, ADCP and CDC is as efficient as rituximab in B cell depletion and antitumor activity
Authors: Christian Klein ,
Centre: Roche Pharma Research and Early Development

You must be registered to reply or comment.

A VARIANT OF OBINUTUZUMAB WITH ABOLISHED ADCC, ADCP AND CDC IS AS EFFICIENT AS RITUXIMAB IN B CELL DEPLETION AND ANTITUMOR ACTIVITY

Christian Klein
Thread initiator
Subspeciality
Reg: 5/23/2015 8:34:00 PM
Comment# 1
I invite healthcare professionals to open debate around the issues raised in my poster, both those relating to research and to clinical practice.

Comment added on 5/23/2015 8:34:00 PM 
     
You must be registered to reply or comment.



Most viewed poster for this congress
Poster: 9
Visits: 649
Title: Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial
Authors: Michael Wang ,
Centre: The University of Texas MD Anderson Cancer Center

Poster most viewed in this topic
Poster: 274
Visits: 159
Title: Novel CD37-Targeting Antibody-Drug Conjugate (ADC), IMGN529, Has Synergistic Activity in Combination with Rituximab in Non-Hodgkin Lymphoma (NHL) Models
Authors: Angela Romanelli , JF Ponte, J Deckert, K OCallaghan, JA Coccia, L Lanieri, S Chicklas, R Ruiz-Soto
Centre: ImmunoGen Inc


 




PosterSessionOnline
Logo Draft
 
Logo Cert